Literature DB >> 24286938

Percutaneous microwave ablation of hepatic tumors: prospective evaluation of postablation syndrome and postprocedural pain.

Anita Andreano1, Stefania Galimberti1, Elvira Franza2, Erica M Knavel3, Sandro Sironi2, Fred T Lee3, Maria Franca Meloni4.   

Abstract

PURPOSE: To prospectively investigate the frequency and severity of postablation syndrome (PAS) and postprocedural pain in a cohort of patients undergoing hepatic microwave ablation.
MATERIALS AND METHODS: From March 2009 to November 2011, 54 consecutive patients undergoing microwave ablation for liver tumors were enrolled. A questionnaire was administered to investigate PAS and pain at 1, 7, and 40 days after ablation. Four patients did not complete all three questionnaires and were excluded from the analysis. Additionally, laboratory tests with results known to significantly increase or decrease after ablation were performed, and ablation parameters were recorded. Potential predictors of PAS and pain at 1 and 7 days were evaluated by a logistic regression model.
RESULTS: Fifty patients underwent a single microwave ablation session, 33 for hepatocellular carcinoma (HCC) and 17 for liver metastasis. Median ablation volumes on computed tomography were 31 cm(3) for HCC and 42 cm(3) for metastasis. Sixty percent of patients experienced PAS in the first week. Aspartate aminotransferase (AST) levels after ablation were significantly associated with PAS during postprocedure days 1-7. Median visual analog scale scores for pain at the puncture site were 1 and 0.24 at 1 and 7 days, respectively. The risk of having at least moderate pain in the first week was significantly related to ablation volume and time and postablation increase in AST level.
CONCLUSIONS: The incidence and severity of PAS with hepatic microwave ablation is similar to that reported for radiofrequency ablation, with the best predictive factor being postablation AST level elevation. Postablation pain was best predicted by total ablation volume and AST level.
© 2013 The Society of Interventional Radiology Published by SIR All rights reserved.

Entities:  

Keywords:  ALT; AST; ECOG; Eastern Cooperative Oncology Group; HCC; IQR; OR; PAS; PS; RF; SD; VAS; alanine aminotransferase; aspartate aminotransferase; hepatocellular carcinoma; i.v.; interquartile range; intravenous; odds ratio; performance status; postablation syndrome; radiofrequency; standard deviation; visual analog scale

Mesh:

Substances:

Year:  2013        PMID: 24286938     DOI: 10.1016/j.jvir.2013.09.005

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  11 in total

1.  Microwave Ablation: Comparison of Simultaneous and Sequential Activation of Multiple Antennas in Liver Model Systems.

Authors:  Colin M Harari; Michelle Magagna; Mariajose Bedoya; Fred T Lee; Meghan G Lubner; J Louis Hinshaw; Timothy Ziemlewicz; Christopher L Brace
Journal:  Radiology       Date:  2015-07-02       Impact factor: 11.105

Review 2.  Complications of image-guided thermal ablation of liver and kidney neoplasms.

Authors:  Kyung Rae Kim; Sarah Thomas
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 3.  Microwave ablation in primary and secondary liver tumours: technical and clinical approaches.

Authors:  Maria Franca Meloni; Jason Chiang; Paul F Laeseke; Christoph F Dietrich; Angela Sannino; Marco Solbiati; Elisabetta Nocerino; Christopher L Brace; Fred T Lee
Journal:  Int J Hyperthermia       Date:  2016-08-02       Impact factor: 3.914

Review 4.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

5.  Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors.

Authors:  Niklas Verloh; Isabel Jensch; Lukas Lürken; Michael Haimerl; Marco Dollinger; Philipp Renner; Philipp Wiggermann; Jens Martin Werner; Florian Zeman; Christian Stroszczynski; Lukas Philipp Beyer
Journal:  Radiol Oncol       Date:  2019-03-03       Impact factor: 2.991

6.  Propofol Compared to Midazolam Sedation and to General Anesthesia for Percutaneous Microwave Ablation in Patients with Hepatic Malignancies: A Single-Center Comparative Analysis of Three Historical Cohorts.

Authors:  Robbert S Puijk; Valentijn Ziedses des Plantes; Sanne Nieuwenhuizen; Alette H Ruarus; Laurien G P H Vroomen; Marcus C de Jong; Bart Geboers; Caroline J Hoedemaker-Boon; Deirdre H Thöne-Passchier; Ceylan C Gerçek; Jan J J de Vries; Petrousjka M P van den Tol; Hester J Scheffer; Martijn R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2019-06-26       Impact factor: 2.740

7.  Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma.

Authors:  Zhaonan Li; Dechao Jiao; Xinwei Han; Guangyan Si; Yahua Li; Juanfang Liu; Yanneng Xu; Bo Zheng; Xun Zhang
Journal:  Cancer Imaging       Date:  2020-01-30       Impact factor: 3.909

8.  Continuous versus pulsed microwave ablation in the liver: any difference in intraoperative pain scores?

Authors:  Dimitrios Filippiadis; Argyro Mazioti; George Velonakis; Athanasios Tsochantzis; Nevio Tosoratti; Alexis Kelekis; Nikolaos Kelekis
Journal:  Ann Gastroenterol       Date:  2020-11-20

9.  Effectiveness and safety of ultrasound-guided percutaneous microwave ablation for hepatic alveolar echinococcosis.

Authors:  Xu Deng; Jing-Jing Wang; Zhi-Xin Wang; Hai-Ning Fan; Hai-Jiu Wang; Han-Sheng Huang; Kai-Qaing Wang; Xiao-Zhou Yang; Jun-Wei Han; Yangdan Cairang
Journal:  BMC Med Imaging       Date:  2022-02-12       Impact factor: 1.930

10.  Pain control for patients with hepatocellular carcinoma undergoing CT-guided percutaneous microwave ablation.

Authors:  Hong-Zhi Zhang; Jie Pan; Jing Sun; Yu-Mei Li; Kang Zhou; Yang Li; Jin Cheng; Ying Wang; Dong-Lei Shi; Shao-Hui Chen
Journal:  Cancer Imaging       Date:  2018-11-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.